Bio-Rad Laboratories (BIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 529,800 | 488,100 | 403,800 | 434,215 | 470,783 |
| Marketable Securities | 1,010,900 | 1,176,400 | 1,208,900 | 1,362,017 | 404,695 |
| Receivables | 460,600 | 452,500 | 489,000 | 494,645 | 423,537 |
| Inventories | 740,700 | 760,000 | 780,500 | 719,316 | 572,239 |
| Other current assets | 27,700 | 30,700 | 26,100 | 23,604 | 10,089 |
| TOTAL | $2,906,200 | $3,030,300 | $3,048,300 | $3,157,976 | $1,990,479 |
| Non-Current Assets | |||||
| PPE Net | 539,900 | 528,100 | 529,000 | 498,612 | 511,639 |
| Investments And Advances | 6,103,600 | 4,839,200 | 7,698,100 | 8,830,892 | 14,387,010 |
| Intangibles | 754,100 | 704,100 | 734,100 | 738,635 | 601,282 |
| Other Non-Current Assets | 272,700 | 262,400 | 289,600 | 275,551 | 308,979 |
| TOTAL | $7,670,300 | $6,333,800 | $9,250,800 | $10,343,690 | $15,808,910 |
| Total Assets | $10,576,500 | $9,364,100 | $12,299,100 | $13,501,670 | $17,799,390 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,300 | 1,200 | 500 | 465 | 489 |
| Accounts payable and accrued liabilities | 129,000 | 122,300 | 144,600 | 135,041 | 141,941 |
| Accrued Expenses | 172,300 | 124,200 | 139,900 | 194,790 | 276,986 |
| Other current liabilities | 141,700 | 147,200 | 161,600 | 169,648 | 127,936 |
| TOTAL | $517,000 | $467,800 | $522,800 | $568,708 | $680,938 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,201,700 | 1,200,400 | 1,199,100 | 1,197,716 | 10,514 |
| Deferred Revenues | N/A | N/A | N/A | N/A | 50,852 |
| Other Non-Current Liabilities | 344,800 | 308,600 | 360,500 | 349,509 | 358,129 |
| TOTAL | $2,605,900 | $2,327,000 | $3,035,100 | $3,317,706 | $3,433,219 |
| Total Liabilities | $3,122,900 | $2,794,800 | $3,557,900 | $3,886,414 | $4,114,157 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 26,990 | 28,011 | 28,518 | 29,596 | 29,932 |
| Common Shares | N/A | N/A | N/A | 3 | 3 |
| Retained earnings | 8,176,300 | 7,416,400 | 9,260,600 | 9,898,203 | 13,525,340 |
| Other shareholders' equity | -188,700 | -538,300 | -335,500 | -466,408 | -175,836 |
| TOTAL | $7,453,600 | $6,569,300 | $8,741,200 | $9,615,252 | $13,685,240 |
| Total Liabilities And Equity | $10,576,500 | $9,364,100 | $12,299,100 | $13,501,666 | $17,799,397 |